Compare Citius Pharmaceuticals Inc (CTXR) vs Roundhill NVDA WeeklyPay ETF (NVDW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Roundhill NVDA WeeklyPay ETF — how do they compare? Citius Pharmaceuticals Inc trades at $0.5 (market cap $13.62M), while Roundhill NVDA WeeklyPay ETF trades at $37.11 (market cap $119.10M). The key difference: Roundhill NVDA WeeklyPay ETF is far larger — about 8.7× Citius Pharmaceuticals Inc's market cap, and Roundhill NVDA WeeklyPay ETF is trading nearer its 52-week high, Citius Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Citius Pharmaceuticals Inc for 17 Days and Roundhill NVDA WeeklyPay ETF for 50 Days on average.
| CTXR | NVDW | |
|---|---|---|
Market Cap | $13.62M | $119.10M |
Volume | 132,438 | 44,838 |
Sector | Health | Income / Options Overlay |
52-Week High | $1.82 | $52.33 |
52-Week Low | $0.48 | $31.88 |
Typical Hold Time | 17 Days | 50 Days |
Enterprise Value | $3.79M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.4994, down 1.73% with a bearish technical signal despite oscillators showing oversold conditions. The company reported $7.1M revenue for the first nine months of 2026 from LYMPHIR commercial sales, but continues to post significant losses with a -651.27% net income margin. Recent news highlights strong commercial momentum for LYMPHIR with 44 institutions ordering the treatment since launch.
The stock presents a high-risk opportunity with analyst consensus strongly bullish (83% buy ratings, $5 price target) but fundamental challenges persist. Key risks include ongoing cash burn and execution of commercial strategy, while potential upside depends on successful LYMPHIR adoption and path to profitability.
NVDW trades at $37.11, down 4.11% today, with technical indicators showing a bullish trend from moving averages but neutral oscillators. The ETF provides weekly dividend income tied to Nvidia's performance with 120% leveraged exposure. Recent Nvidia earnings beat expectations, supporting the AI theme's momentum, though the fund carries elevated risk due to leverage and NAV volatility during Nvidia downturns.
The outlook remains tied to Nvidia's AI-driven growth, offering high-yield income potential but with significant volatility risk. Investors face exposure to Nvidia's stock performance amplified by leverage, making the fund suitable for risk-tolerant income seekers but vulnerable to sharp corrections in the underlying asset.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Roundhill NVDA WeeklyPay ETF
NVDW is an actively managed ETF that seeks to provide weekly distributions and returns equal to 1.2 times (120%) the calendar week performance of Nvidia (NVDA) common shares. It combines modest leverage with a high-frequency payout schedule, designed for investors who want amplified exposure to Nvidia alongside a consistent weekly income stream.
Read more on NVDW →
